DOP2016000009A - Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen - Google Patents

Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen

Info

Publication number
DOP2016000009A
DOP2016000009A DO2016000009A DO2016000009A DOP2016000009A DO P2016000009 A DOP2016000009 A DO P2016000009A DO 2016000009 A DO2016000009 A DO 2016000009A DO 2016000009 A DO2016000009 A DO 2016000009A DO P2016000009 A DOP2016000009 A DO P2016000009A
Authority
DO
Dominican Republic
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
isoquinoline compounds
new isoindoline
Prior art date
Application number
DO2016000009A
Other languages
English (en)
Inventor
Arnaud Le Tiran
Thierry Le Diguarher
Jean-Michel Henlin
Guillaume De Nanteuil
Imre Fejes
Miklos Nyerges
James Brooke Murray
Andras Kotschy
Zoltan Szlavik
James Edward Paul Davidson
I-Jen Chen
Claire Walmsley
Mark Dodsworth
Johannes W G Meissner
Paul Brough
Janos Tatai
Olivier Geneste
Jérôme-Benoît Starck
Anne-Françoise Guillouzic
Original Assignee
Vernalis R&D Ltd
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis R&D Ltd, Servier Lab filed Critical Vernalis R&D Ltd
Publication of DOP2016000009A publication Critical patent/DOP2016000009A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

Compuestos de fórmula (I): en la que Het, R3, R4, R5, R7, R8, R9, T, p, p’, q, y q’ son como se han definido en la descripción. Medicamentos.
DO2016000009A 2013-07-23 2016-01-11 Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen DOP2016000009A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1357276A FR3008977A1 (fr) 2013-07-23 2013-07-23 Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
DOP2016000009A true DOP2016000009A (es) 2016-03-15

Family

ID=49911606

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000009A DOP2016000009A (es) 2013-07-23 2016-01-11 Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen

Country Status (49)

Country Link
US (3) US9809574B2 (es)
EP (1) EP3024826B1 (es)
JP (1) JP6395829B2 (es)
KR (1) KR102008431B1 (es)
CN (2) CN109456324B (es)
AP (1) AP2016008989A0 (es)
AR (1) AR097009A1 (es)
AU (1) AU2014295101B2 (es)
BR (1) BR112016001080B1 (es)
CA (1) CA2919572C (es)
CL (1) CL2016000148A1 (es)
CR (1) CR20160030A (es)
CU (1) CU24352B1 (es)
CY (1) CY1121247T1 (es)
DK (1) DK3024826T3 (es)
DO (1) DOP2016000009A (es)
EA (1) EA032301B1 (es)
ES (1) ES2711371T3 (es)
FR (1) FR3008977A1 (es)
GE (1) GEP20207070B (es)
HK (2) HK1218754A1 (es)
HR (1) HRP20190277T1 (es)
HU (1) HUE041443T2 (es)
IL (1) IL243449A0 (es)
JO (1) JO3457B1 (es)
LT (1) LT3024826T (es)
MA (1) MA38801B1 (es)
MD (1) MD4793C1 (es)
ME (1) ME03346B (es)
MX (1) MX365373B (es)
MY (1) MY193619A (es)
NI (1) NI201600016A (es)
NZ (1) NZ716155A (es)
PE (1) PE20160241A1 (es)
PH (1) PH12016500034B1 (es)
PL (1) PL3024826T3 (es)
PT (1) PT3024826T (es)
RS (1) RS58344B1 (es)
RU (1) RU2689305C2 (es)
SA (1) SA516370439B1 (es)
SG (1) SG11201600205XA (es)
SI (1) SI3024826T1 (es)
TN (1) TN2016000003A1 (es)
TR (1) TR201819155T4 (es)
TW (1) TWI560184B (es)
UA (1) UA117490C2 (es)
UY (1) UY35664A (es)
WO (1) WO2015011164A1 (es)
ZA (1) ZA201600198B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN109311874B (zh) 2016-04-20 2021-07-30 百时美施贵宝公司 经取代的二环杂环化合物
CA3103954A1 (en) 2018-06-27 2020-01-02 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
CN112010796B (zh) * 2020-09-17 2022-04-22 浙江大学 光学活性3-(1,1-二氟-2-氧-2-芳基乙基)异吲哚啉-1-酮衍生物制备方法
WO2023161317A1 (en) 2022-02-24 2023-08-31 Les Laboratoires Servier 5-[7-(3,4-dihydro-1h-isoquinoline-2-carbonyl)-1,2,3,4 tetrahydroisoquinolin-6-y l]-1h-pyrrole-3-carboxamide derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2484209C (en) 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
WO2004096774A1 (en) 2003-05-01 2004-11-11 Glaxo Group Limited Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
ZA200702257B (en) * 2004-08-20 2009-06-24 Univ Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
WO2006023778A2 (en) * 2004-08-20 2006-03-02 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
RU2007128987A (ru) * 2005-02-15 2009-03-27 Ново Нордиск А/С (DK) 3,4-дигидро-1н-изохинолин-2-карбоновой кислоты 5-аминопиридин-2-2-иловые эфиры
KR101511074B1 (ko) 2007-04-16 2015-04-13 애브비 인코포레이티드 7-치환된 인돌 Mcl-1 억제제
CN102007101A (zh) 2007-11-30 2011-04-06 生物区科学管理控股有限公司 作为抗菌剂的四氢-异喹啉ppat抑制剂
JP5496915B2 (ja) 2008-02-13 2014-05-21 シージーアイ ファーマシューティカルズ,インコーポレーテッド 6−アリール−イミダゾ[1,2−a]ピラジン誘導体、その製造方法、及びその使用方法
US7984530B2 (en) 2008-02-14 2011-07-26 Tory Reynolds Pet waste vacuum system and apparatus, disposable liners therefor, and a method of collecting pet waste using same
US9346795B2 (en) * 2011-05-25 2016-05-24 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic Bcl inhibitors
CN104125954A (zh) * 2011-12-23 2014-10-29 诺华股份有限公司 用于抑制bcl2与结合配偶体相互作用的化合物
WO2013100890A1 (en) 2011-12-27 2013-07-04 Intel Corporation Methods and systems to control power gates during an active state of a gated domain based on load conditions of the gated domain
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
TWI560184B (en) 2016-12-01
MD4793B1 (ro) 2022-02-28
SA516370439B1 (ar) 2019-06-27
BR112016001080B1 (pt) 2022-04-05
EP3024826A1 (en) 2016-06-01
LT3024826T (lt) 2019-02-25
JP2016525529A (ja) 2016-08-25
EP3024826B1 (en) 2018-11-14
AR097009A1 (es) 2016-02-10
AU2014295101A1 (en) 2016-02-04
JO3457B1 (ar) 2020-07-05
HRP20190277T1 (hr) 2019-04-05
CN105431422A (zh) 2016-03-23
MD20160018A2 (ro) 2016-07-31
US20200262816A1 (en) 2020-08-20
IL243449A0 (en) 2016-02-29
AP2016008989A0 (en) 2016-01-31
RU2689305C2 (ru) 2019-05-27
CA2919572C (en) 2017-06-20
KR102008431B1 (ko) 2019-08-07
US11028070B2 (en) 2021-06-08
MA38801A1 (fr) 2018-05-31
PE20160241A1 (es) 2016-04-30
CN105431422B (zh) 2019-08-30
UA117490C2 (uk) 2018-08-10
CU20160010A7 (es) 2016-06-29
GEP20207070B (en) 2020-02-25
ZA201600198B (en) 2019-07-31
HUE041443T2 (hu) 2019-05-28
MD4793C1 (ro) 2022-09-30
MA38801B1 (fr) 2019-03-29
SI3024826T1 (sl) 2019-03-29
US9809574B2 (en) 2017-11-07
MX2016000904A (es) 2016-04-25
AU2014295101B2 (en) 2018-05-31
UY35664A (es) 2015-01-30
CN109456324B (zh) 2022-04-22
PL3024826T3 (pl) 2019-05-31
BR112016001080A2 (es) 2017-07-25
PH12016500034A1 (en) 2016-03-28
WO2015011164A1 (en) 2015-01-29
EA201600122A1 (ru) 2016-07-29
ME03346B (me) 2019-10-20
PT3024826T (pt) 2019-01-28
CA2919572A1 (en) 2015-01-29
DK3024826T3 (en) 2019-03-04
NI201600016A (es) 2016-02-11
TN2016000003A1 (en) 2017-07-05
TW201504228A (zh) 2015-02-01
HK1222856A1 (zh) 2017-07-14
TR201819155T4 (tr) 2019-01-21
US10689364B2 (en) 2020-06-23
HK1218754A1 (zh) 2017-03-10
MY193619A (en) 2022-10-20
KR20160033224A (ko) 2016-03-25
SG11201600205XA (en) 2016-02-26
CN109456324A (zh) 2019-03-12
CU24352B1 (es) 2018-07-05
CL2016000148A1 (es) 2016-08-12
MX365373B (es) 2019-05-31
CR20160030A (es) 2016-03-09
NZ716155A (en) 2019-05-31
US20180002313A1 (en) 2018-01-04
EA032301B1 (ru) 2019-05-31
CY1121247T1 (el) 2020-05-29
FR3008977A1 (fr) 2015-01-30
JP6395829B2 (ja) 2018-09-26
RU2016106003A (ru) 2017-08-28
US20160194304A1 (en) 2016-07-07
ES2711371T3 (es) 2019-05-03
RS58344B1 (sr) 2019-03-29
PH12016500034B1 (en) 2016-03-28

Similar Documents

Publication Publication Date Title
SV2017005587A (es) Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceutacas que los contienen
ECSP17083003A (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP17082825A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2014000282A (es) Nuevos derivados tienopirimidina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen
CR20170590A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2014000163A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
DOP2014000154A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
DOP2016000009A (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20160031A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35653A (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
SV2014004879A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen